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Abstract
Background: Antigenic variation is an effective way by which viruses evade host immune defense leading to viral
persistence. Little is known about the inhibitory mechanisms of viral variants on CD4 T cell functions.
Results: Using sythetic peptides of a HLA-DRB1*15-restricted CD4 epitope derived from the non-structural (NS) 3
protein of hepatitis C virus (HCV) and its antigenic variants and the peripheral blood mononuclear cells (PBMC)
from six HLA-DRB1*15-positive patients chronically infected with HCV and 3 healthy subjects, the in vitro immune
responses and the phenotypes of CD4
+CD25
+ cells of chronic HCV infection were investigated. The variants
resulting from single or double amino acid substitutions at the center of the core region of the Th1 peptide not
only induce failed T cell activation but also simultaneously up-regulate inhibitory IL-10, CD25
-TGF-b
+ Th3 and CD4
+IL-10
+ Tr1 cells. In contrast, other variants promote differentiation of CD25
+TGF-b
+ Th3 suppressors that attenuate
T cell proliferation.
Conclusions: Naturally occuring HCV antigenic mutants of a CD4 epitope can shift a protective peripheral Th1
immune response into an inhibitory Th3 and/or Tr1 response. The modulation of antigenic variants on CD4
response is efficient and extensive, and is likely critical in viral persistence in HCV infection.
Background
It is estimated that hepatitis C virus (HCV) infects at
least four million Americans and more than 120 million
individuals globally [1]. Each year in the United States
an additional 30,000 new infections occur; and over 70%
of patients develop chronic infection leading to end
stage of liver diseases and in many cases, death [2,3]. It
is clear that an effective anti-viral cellular immune
response is critical for viral clearance and prevention of
chronic HCV infection [4-14]. Recent studies also
reported the importance of innate immunity and inter-
feron lambda in the control of HCV infection [15,16].
H o w e v e r ,t h em e c h a n i s m sb yw h i c hH C Ve v a d e sh o s t
immune defenses and establishes persistent infection
remain to be elucidated. It is known that antigenic var-
iation is an effective way by which viruses avoid immune
recognition and may play a critical role in the develop-
ment of viral persistence in infections with HCV [17],
human immunodeficiency virus (HIV) [18], influenza
virus and other viral diseases [19].
RNA viruses evolve at very rapid rates, which is due to
the lack of a proofreading capacity of the RNA-depen-
dent RNA polymerase [20], a characteristic that is
recognized as the basis of their adaptability. Consistent
with this, HCV in an infected patient consists of quasi-
species that have distinct but closely related RNA
sequences. Current hypotheses relate the tendency of
HCV infection to persist to the existence of virus quasi-
species and emergence of antigenic variants driven by
immune selection [21-24]. Meaningful antigenic varia-
tion results from mutations in protein regions targeted
by antibody and T cells [25]. There is evidence that
naturally occurring variants of CD8 epitopes act as T-
cell receptor antagonists for antiviral cytotoxic T cell
response [17,18,26,27]. A recent study showed that HCV
accumulates clustered mutations within an immune-
dominant epitope, viral protein RdRp which is bound by
HLA-B27 molecule. HCV escapes CD8 T-cell immune
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RdRp fragment [28]. Large viral diversity during the
acute phase of HCV infection has been associated with
the progression to chronic infection, whereas recovery
from infection has been associated with relatively smal-
ler viral diversity [19].
T-helper (Th) CD4 cells, the other key component of
adaptive immunity, also play a major role in host
defense against viruses and intracellular microbes [29].
Clonal expansion and maintenance of CD8 activity
depend upon specific Th1 cells [30]. A protective Th1
response, characterized by Th1 cytokines such as inter-
feron (IFN)-g is essential for viral clearance. It was
reported that the absence of an adequte CD4 response
is associated with incomplete control of HCV replication
by memory CD8 cells and failure to resolve HCV infec-
tion [29]. A strong HCV-specific Th1 response was
observed in patients who resolved acute HCV infection,
whereas patients who were unable to mount a CD4
response developed chronic infection [29,31]. The
mechanisms by which HCV escapes CD4 responses are
remained unclear. Understanding how HCV escapes an
initial CD4 response should provide insight into the
pathogenesis of chronic HCV infection.
Unlike HIV, HCV does not cause a systemic ablation
of the immune system but rather is associated with a
form of specific tolerance such that immune responses
to HCV are blunted and are unable to eliminate the
viruses [8]. Regulatory T (Treg) cells are central to the
control of immune reactivity [32] and are important in
organ transplantation [33]. Antigen inducible Tregs act
to suppress inflammation andp r e v e n tt i s s u ea n do r g a n
injury during responses to infection, mainly by secretion
of IL-10 (Tr1) and TGF-b (Th3)[32]. Studies by others
have shown that CD4
+CD25
+ Tregs and IL-10-produ-
cing Tr1 cells modulate the proliferation of HCV-speci-
fic CD4 and CD8 cells in patients infected with HCV
for 20~30 years [34-37]. These data may reflect a well
established immune tolerance after lengthy HCV infec-
tion. Yet, it is not clear what mechanisms induce
expression of Tregs, the precise phenotypes of Tregs
that are involved in developing immune suppression and
what role HCV antigenic variants play in immune eva-
sion during the early course of infection.
Our previous studies using peripheral blood mono-
nuclear cells (PBMCs) from a patient infected with HCV
for about 2.5-4 years identified a Th1 epitope and its
variants derived from the non-structural (NS) 3 protein
of HCV [38]. We also found that variants of the Th1
epitope can effectively suppress host polyclonal periph-
eral T cell proliferation, and shift the cytokine secretion
patterns from one characteristic of a Th1 antiviral
responses to a Th2 form [39,40]. In the present study
we show how such CD4 variants act as antigenic
variants that modulate T-cell function through multiple
mechanisms in early HCV infection.
Materials and methods
Patient samples
All samples were obtained with informed consent and
approval of the local Institutional Review Board (IRB).
Peripheral blood samples were collected from a patient
(B3019) with chronic hepatitis at about 18~28 months
and four years after infection. PBMCs were isolated as
described previously [40]. The HLA-class II alleles of
this patients are HLA-DR*1501 and DR*0701. PBMCs
from five HLA-DRB1*15-positive patients and three
healthy DRB1*15-positive individuals were also used for
in vitro detection of CD4
+CD25
+ Tregs. Fresh PBMCs
from additional six patients infected with HCV for
about 2~5 years and six healthy individuals were also
isolated and used for determination of in vivo levels of
CD4
+CD25
+ Tregs. The detailed information of HCV-
infected patients is listed (see Additional File 1, Table
S 1 ) .T h ep r e s e n c eo fH C V - s p e c i f i ca n t i b o d i e si n
patients’ sera and HCV genotypes were determined as
described previously [40].
Peptides
A CD4 epitope derived from the non-structural (NS) 3
protein of HCV and its antigenic variants were identified
as previously described [40,41]. Peptides corresponding
to wild type and variant sequences of NS3358-375 were
synthesized [40,41]. The sequences of NS3358-375 wild
type and variant peptides are listed in Table 1. Variant
peptides were also pooled into two groups, VP1 and
VP2 (Figure 1D), according to their proliferation
responses for further experiments.
Table 1 Synthetic peptides of NS3358-375 and its variants
Peptide name Amino acid sequence Time of
isolation*
Wild
type
NS3358-
375
VIKGGRHLIFCHSKKKCD
VP1** I366T
F367L
——————TL—————— 1.0
C368R ————————R————— 1.0
H369R —————————R———— 1.0
S370P ——————————P——— 1.0, 2.4
K371E ———————————E—— 1.0
C374R ——————————————R- 2.4
VP2 V358G G——————————————— 1.0
V358A
I366V
A—————V——————— 1.0
I366V ——————V——————— 2.4
C374S ——————————————S- 2.4
*: years after infection. **: VP means variant pool.
Note: the core region of NS3358-37 encompasses amino acids 364-373.
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Proliferation with each peptide was performed as
described previously [39].
T cell proliferation with variant pools of VP1 and
VP2 was measured using thymidine incorporation
assay as described previously [39]. In this assay, PBMC
were re-suspended at a concentration of 10
6/ml in
RPMI 1640 tissue culture medium containing 25 mM
HEPES, 2.0 mM L-glutamine, 100 U/ml penicillin, 100
μg/ml streptomycin, and 10% pooled human plasma
(PHP). Two 100 μl aliquots of PBMC mentioned above
were cultured with either wild peptide NS3358-375 (5
μM) or variant-peptide pool VP1 and VP2 (1 μM/each
peptide) for three hours in 96-well round bottom
plates. Then 15 μg/ml of each antibody to human IL-
10 (Pierce Endogen, Rockford, IL, USA), CD25, and
TGF-b1 (BD biosciences, San Diego, CA, USA) were
added. Parallel cultures containing either wild type
peptide, or variant-peptide pools without antibody, or
PBMC with medium alone were used as controls. Cul-
tures were incubated at 37°C in 5% humidified CO2.
At day four, cells were pulsed overnight with 1.0 μCi/
well tritiated thymidine. Radioactive label incorpora-
tion (cpm) was measured at day five. PBMC stimulated
with wild type NS3358-375 alone and medium without
antigen were used as positive and negative controls
respectively. Results were represented as mean ± SEM
cpm of duplicate cultures.
Anergy assay
To measure induction of unresponsiveness by variant
NS3 peptides, PBMCs were pulsed with 0.1 of each var-
iant peptide for 3 hours at 37°C. Free peptide was
washed out and 100 μl aliquots of the cells at 1 × 10
6/
ml were added to wells containing wild type NS3358-375
peptide at 10 μM. After 65 hours, cultures were assessed
for proliferation by thymidine incorporation. PBMC sti-
mulated with wild type NS3358-375 alone and medium
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Figure 1 Proliferation in response to peptides of wild-type NS3358-375 and its variants and binding affinity of those peptides to HLA-
DRB1*1501 molecules. A and B: PBMC from a HCV-infected patient B3019 were cultured with wild type NS3358-375 and variant peptides at the
given concentrations, to six days, pulsed overnight with 1.0 μCi/well tritiated thymidine. Radioactive label incorporation (cpm) was measured.
PBMC with tissue culture medium alone was used as a negative control. Experiments were performed in triplicate. A representative of five
experiments is shown. C and D: Binding of biotinylated peptides to HLA-DRB1*1501 molecules were assessed using an antigen-capture ELISA.
Overnight binding affinities of variant peptides were compared to wild type peptide NS3358-375. A representative of three experiments is shown.
E and F: PBMCs were pre-pulsed with 0.1 μM variant peptides for three hours, then re-challenged with wild type NS3358-375 at a concentration
of 10 μM. Rest of the experiment was as same as mentioned in A. A representative of five experiments is shown.
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trols respectively.
Peptide binding
An assay for in vitro peptide binding was developed as
previously described to determine relative HLA binding
levels of wild type and variant peptides [39]. Binding
affinities of biotinylated-variant peptides to HLA-
DRB1*1501 molecules were compared to that of wild
type peptide.
Cytokine ELISA
ELISAs for IL-2, IL-10, IFN-g and TGF-b were per-
formed using specific ELISA kits according to manufac-
turer’s instruction (BD Pharmingen) as described
previously [39].
Intracellular cytokine staining and flow cytometry
Antibodies and reagents
The following antibodies from BD Biosciences were
used for cell separation and staining: purified mAb for
human CD4, FITC-conjugated IFN-g, IL-2, PE-conju-
gated IL-10 and CD152 (CTLA-4), APC-conjugated
CD25, biotinylated-TGF-b1, PECy7-conjugated-strepta-
vidin, FITC-conjugated mouse IgG1, PE-conjugated
mouse IgG 2a and rat IgG 2a, biotin-conjugated rat
IgG2a. FITC-conjugated Foxp3 (eBiosciences) and ECD-
conjugated CD25 and mouse IgG2a (Beckman Coulter,
Miami, FL, USA) were also used.
Separation of CD4
+ cells
PBMCs were re-suspended at a concentration of 1 ×
10
6 /ml in RPMI 1640 tissue culture medium as men-
tioned above in the description of the proliferation
assay. 1 ml aliquots of PBMC were added to a 24-well
tissue culture plate containing each wild type NS3358-
375 or variant pool, and medium alone. The concentra-
tions of peptides are 5 μMf o rN S 3 358-375 and 1 μM
for each of variant peptides. After culturing for 66
hours, the PBMCs were treated with anti-human CD4
antibodies and magnetic micro-beads (Miltenyi Biotec,
Auburn, CA) for positive selection of CD4 cells using
a Magnetic Cell Separator (MACS, Miltenyi Biotec).
T h ep u r i t yo fC D 4
+ cells obtained was 99.3% deter-
mined by Flow Cytometry.
Cellular staining and flow cytometry assay
The purified CD4
+ cells were treated with 0.5 ml of
fix/permeabilizing solution (BD Pharmingen) for 10
minutes. After washing, the appropriate volume of spe-
cific fluorescent-labeled anti-CD25-ECD, anti-IFN-g-
FITC, anti-IL-10-PE, anti-TGF-b1-biotin and streptavi-
din-CyChrome were added to each of the tubes. One
additional tube of CD4
+ cells were incubated with
Foxp3-FITC, CD152 (CTLA-4)-PE and CD25-ECD. A
tube of pooled CD4
+ cells from each culture was
stained with isotype antibodies equivalent to each of
the antibodies described above. In addition, four tubes
of pooled CD4
+ cells were stained with each of the
above antibodies alone as single-color controls which
is necessary for color compensation. All tubes were
incubated for 30 minutes in dark at room temperature.
After washing, cells were re-suspended in 300 μlo f
wash buffer (BD Pharmingen), and a four color or
three-color flow cytometry assay was performed within
24 hours at the Flow Cytometry Service Laboratory of
the University of Illinois at Chicago. A total 1 × 10
5
cells were counted to determine the ratio of CD25
+,
CD25
- and cytokine producing cells of each CD4
+
population.
Statistical analysis
The phenotypes of CD4
+CD25
+ Tregs of the six HLA-
DRB1*15-positive patients and three healthy subjects
were summarized in Table 2. The in vivo Treg levels
and phenotypes of six other patients and six healthy
subjects are shown in Table 3. Data are expressed as
medians and ranges (Table 2). The p-values are from a
Wilcoxon non-parametric t-test.
Table 2 Phenotypes of CD4+CD25+ cells induced by HCV
variants
Median (range) (%)
CD4+ cells HCV- (n = 3) HCV+ (n = 6) p value*
Medium
CD25+ 8.31 (6.0 - 11) 23.4 (19 - 28) 0.03
TGFb+ 5.28 (3.5 - 9.0) 56.0 (46 - 61) 0.01
IL-10+ 3.22 (2.5 - 3.5) 7.54 (6.0 - 17) 0.04
TGFb+ IL-10+ 0.67 (2.0 - 5.5) 7.85 (5.0 - 14) 0.04
NS3358-375
CD25+ 10.1 (10 - 14) 21.6 (18 - 27) 0.02
TGFb+ 5.04 (2.0 - 8.5) 55.4 (37 - 59) 0.01
IL-10+ 2.95 (2.6 - 3.2) 6.51 (3.0 - 11) 0.03
TGFb+ IL-10+ 0.67 (0.5 - 2.5) 7.85 (5.0 - 12) 0.002
VP1
CD25+ 10.2 (7.0 - 13) 29.9 (21 - 48) 0.01
TGFb+ 6.18 (2.0 - 14) 57.1 (42 - 61) 0.06
IL-10+ 5.77 (3.5 - 7.5) 6.23 (5.0 - 13) 0.33
TGFb+ IL-10+ 7.84 (2.0 - 6.5) 8.65 (5.0 - 15) 0.21
VP2
CD25+ 8.60 (5.0 - 13) 29.3 (23 - 51) 0.02
TGFb+ 7.04 (3.0 - 13) 58.8 (44 - 67) 0.04
IL-10+ 6.57 (6.0 - 8.5) 7.73 (5.5 - 12) 0.36
TGFb+ IL-10+ 3.05 (2.5 - 7.0) 9.36 (5.0 - 17) 0.07
*: Wilcoxon non-parametric t-test
All subjects are positive for HLA-DRB1*15.
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Lack of response to HCV antigenic variants
Our previous studies identified a CD4 epitope derived
from the NS3 protein of HCV, NS3358-375 [38]. This epi-
tope is human leukocyte antigen DRB1*15 (HLA-
DRB1*15)-specific, since it binds to HLA-DRB1*1501
well, but not to the other class II allele of the patient,
HLA-DRB1*07 [39]. Antigenic variants of the Th1 epi-
tope were identified by RT-PCR, cloning and sequencing
[41]. Peptides of wild type NS3358-375 and its variants
(single or double amino acid substitutions) were synthe-
sized and used in the current study (Table 1).
NS3358-375 variant peptides were compared to wild type
peptide in T-cell proliferation assays with PBMCs col-
lected from patient B3019 at about four years after HCV
infection. Proliferation was abolished in the presence of
variant peptides I366TF367L, C368R, H369R, S370P,
K371E and C374R (Figure 1A: failed responses), and atte-
nuated by variants V358G, V358AI366V, I366V and
C374S (Figure 1B: attenuated responses). These two
groups comprise 55% of the total number of the variants
tested. Among the remaining variants, 39% (7/18) stimu-
lated T cell proliferation at the levels compatible to that
of wild type peptide; and only one variant, I366V (1/18,
6%), stimulated stronger T cell proliferation compared to
wild type peptide (data not shown). Flow cytometry ana-
lysis showed that greater than 95% of peripheral prolifer-
ating cells stimulated by wild type NS3358-375 were CD4
+.
These data are consistent with our previous studies of
three DRB1*15
+ patients infected with HCV [39]. Com-
pared to our previous study (36), more variants showed
inhibitory effect on T cell proliferation as shown in Fig-
ure 1A and 1B. The data reflects the progress of immune
inhibition during the evolution of HCV infection.
When PBMCs were pre-pulsed with 0.1 μM of each
variant peptide for three hours, then re-challenged with
wild type NS3358-375 at a concentration of 10 μM, the
cells showed greatly reduced responsiveness characteris-
tic of anergy (Figure 1E-F). Even the variant peptides sti-
mulating T cell proliferation at compatible levels as wild
type peptide induced anergy (data not shown).
To determine whether failure to stimulate prolifera-
tion might be caused by a failure to bind the HLA-
DR15 molecules, binding of biotinylated variant peptides
to DRB1*15 molecules were compared to wild type
NS3358-375 in an antigen capture ELISA. As shown in
Figure 1C and 1D, dose-dependent binding was
observed for each variant at levels comparable to or in
excess of wild type peptide. These results demonstrate
that the failure to stimulate T-cell proliferation cannot
be explained as a failure to bind HLA molecules on the
surface of antigen presenting cells (APC).
The suppression by antigenic variants is mediated by IL-
10 or TGF-b
+ cells
We reasoned that the effect of CD4 variants on immune
responses in vivo should be the combined effect of all or
some of the variants since viral variants do not exist in
isolation in vivo. Therefore, we pooled the variant pep-
tides into two groups, VP1 and VP2 (Table 1), according
to their proliferation responses (Figure 1A and 1B) to
better reflect the effect of CD4 variants on T cell
responses in vivo.
We evaluated whether immunoregulatory cytokines
such as IL-10 and TGF-b or CD25
+ regulatory cells play
a role in the immune inhibition induced by VP1 and
VP2. PBMCs were cultured with wild type peptide
NS3358-375 and variant-peptide pools of VP1 and VP2 in
the presence or absence of antibodies to human IL-10,
TGF-b1 and CD25. As shown in Figure 2, the inhibition
on T cell proliferation induced by VP1 was restored to
the level of wild type peptide by anti-IL-10 (Figure 2B)
and was partially restored by antibodies to CD25 and
TGF-b (Figure 2A and 2B). These results demonstrate
that IL-10 elaboration alone was sufficient to suppress T
cell proliferation. In contrast, the inhibition induced by
VP2 was completely blocked by antibodies to CD25 and
TGF-b and was partially reversed by IL-10 antibody
(Figure 2A and 2B), indicating that CD25
+ and TGF-b
are critical in the inhibition by VP2. Consistent with
these results, VP1 induced higher levels of IL-10 than
wild type peptide and VP2, and VP2 induced lower
levels of IL-10 and higher levels of TGF-b (Figure 2G).
VP2 also induced similar level of IL-2 compared to wild
type peptide, and both VP1 and VP2 induced lower
levels of IFN-g than that of wild type peptide (Figure
2G), suggesting modulation of a Th1 response by both
VP1 and VP2 peptides.
Table 3 Phenotypes of CD4+ regulatory cells in early
HCV infection
Median (range) (%)
CD4+ cells HCV- (n = 3) HCV+ (n = 6) p value*
CD25+ 9.50 (9.1 - 10) 20.9 (17 - 34) 0.02
TGFb+ 2.89 (1.3 - 8.4) 30.0 (25 - 37) 0.02
IL-10+ 3.02 (1.6 - 5.1) 5.64 (2.0 - 16) 0.04
IFNg+ 5.04 (1.6 - 9.8) 5.14 (2.9 - 8.7) 0.81
TGFb+ IL-10+ 1.33 (0.3 - 3.4) 5.03 (1.4 - 9.3) 0.05
TGFb+ IFNg+ 1.52 (0.7 - 5.0) 2.01 (0.9 - 6.8) 0.54
CD25- 56.0 (52 - 58) 51.3 (48 - 54) 0.07
TGFb+ 1.43 (0.7 - 4.2) 26.5 (20 - 33) 0.02
IL-10+ 0.42 (NA**) 0.92 (0.5 - 6.8) NA
IFNg+ 2.15 (0.9 - 3.2) 2.31 (0.4 - 7.3) 0.81
TGFb+ IL-10+ 0.08 (NA) 0.40 (0.2 - 2.5) NA
TGFb+ IFNg+ 0.07 (0.05 - 1.1) 0.70 (0.03 - 1.1) 0.2
*: Wilcoxon non-parametric t-test.
**: number of control subjects is less than 2.
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+ or TGF-b
+ Tregs
were directly involved in the inhibitory effect of HCV
variants, CD25
+ or TGF-b
+ cells were deleted from
PBMCs using antibodies to CD25 and TGF-b as well as
magnetic beads. TGF-b exists either inside of TGF-b-
secreting cells or bound to the surface of cells expres-
sing TGF-b receptors. It is possible that TGF-b-secret-
ing cells express TGF-b receptors as well. Thus the
deletion of TGF-b
+ cells could be deleted both the
TGF-b receptor expressing cells and the TGF-b-secret-
ing cells. Those deleted cells are called TGF-b
+ cells
here after. The remaining CD25
- or TGF-b
- cells were
cultured with either wild type peptide or VP1 and VP2,
and the proliferation was measured at day five. As
shown in Figure 2D, the suppressive effect on prolifera-
tion by VP1 and VP2 was substantially reduced by
deletion of TGF-b
+ cells indicating a crucial role of
TGF-b
+ Th3 cells in the immune modulation induced
by antigenic variants. An example of CD4
+ CD25
+ cells
induced by VP1 cultured with anti-TGF-b antibodies or
with deletion of TGF-b
+ cells is shown (see Additional
File 2, Figure S1). Deletion of CD25
+ cells only partially
reverted the suppressions by both VP1 and VP2 suggest-
ing the possibility of the involvement of CD25
- suppres-
sors in the reaction.
In order to evaluate whether soluble TGF-b or TGF-
b-producing Th3 cells played a critical role in the inhi-
bition by antigenic variants, we co-cultured PBMC and
VP1 or VP2 with a supernatant pool consisting of
supernatant from each culture of VP1 or VP2 with
PBMC. The supernatant pool contained TGF-b at a
concentration of 690 pg/ml determined by ELISA as
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Figure 2 Secreted IL-10, CD25
+ and TGF-b-bound cells were involved in the inhibition by HCV variants. A-B: PBMCs were cultured with
peptide NS3358-375 (5 μM), variant-peptide pool VP1, or VP2 (1 μM/each peptide) for three hours, then 15 μg/ml of each antibody to human IL-
10, CD25 and TGF-b were added. Parallel cultures with either NS3358-375 or VP1 and VP2 without antibody, and PBMC with medium alone were
used as controls. At day four, cells were pulsed overnight with 1.0 μCi/well tritiated thymidine. Radioactive label incorporation (cpm) was
measured at day five. C-D. CD25
+ or TGF-b-bound cells were deleted from PBMCs using antibodies to CD25
+ or TGF-b and magnetic beads. The
remaining cells were cultured with either NS3358-375 or VP1 and VP2. Proliferation measurement and controls were the same as described in A-B.
E:5 0μl of a supernatant pool alone or the pool with 15 μg/ml TGF-b antibody was added into each culture of PBMC with VP1 or VP2. The
supernatant pool consisted of each culture of VP1 and VP2 described in A. F. PBMCs without TGF-b-bound cells were cultured with VP1 or VP2
and 50 μl of the supernatant pool. All experiments were repeated twice, a single representative experiment is shown G. Levels of IFN-g, IL-10
and TGF-b induced by peptide NS3358-375, VP1 and VP2 were determined by cytokine-specific ELISA. Each 100 μl of supernatant from the
cultures described in A was used for ELISA analysis of IFN-g, IL-10 and TGF-b. Experiments were performed in duplicate. A single representative
of five experiments is shown.
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Page 6 of 13previously described [40]. TGF-b in the supernatant
pool was neutralized by TGF-b antibody, and then the
supernatant was added into each culture containing VP1
or VP2. Cultures with peptide alone or peptide plus
supernatant pool without neutralization of TGF-b were
used as controls. As shown in Figure 2E and 2F, neutra-
lization of TGF-b in the supernatant pool did not
restore responses to VP1 and VP2. However deletion of
TGF-b
+ cells did restore the responses even in the pre-
sence of the supernatant pool containing TGF-b.T h e s e
findings suggest that TGF-b
+ Th3 cells rather than solu-
ble TGF-b play a key role in a cell-contact mechanism
in the immune inhibition caused by antigenic variants
during early HCV infection. These observations also
suggest that the mechanisms of immune modulation
induced by VP1 and VP2 are distinct: it is mediated by
IL-10 and CD25
-TGF-b
+ cells for VP1 whereas by CD25
+TGF-b
+ cells for VP2. Taken together, these findings
indicate that HCV variants actively up-regulate a sup-
pressive response rather than simply down-regulate a
protective Th1 response.
Phenotypes of pathogen-inducible Tregs driven by
antigenic variants
We sought to determine the Treg phenotypes responsi-
ble for IL-10 or TGF-b-mediated immune modulation
by antigenic variants in early HCV infection. We
detected CD4
+CD25
+ and CD4
+CD25
- cells and their
cytokine secretion of IFN-g,I L - 1 0a n dT G F - b by intra-
cellular staining and flow cytometry. As shown in Figure
3A, VP2 induced significantly higher ratios of CD4
+CD25
+ cells (50.4%) than wild-type peptide (26.0%) and
VP1 (24.2%). A large proportion (57.5%~66.7%) of the
CD4
+CD25
+ cells were TGF-b
+ (Figure 3B, sum of the
upper two quadrants), providing supporting evidence for
the involvement of CD25
+TGF-b
+ Th3 cells in the
immune transition caused by VP2. As controls, the
PBMCs from a HLA-DRB1*15
+ and HCV-negative
healthy individual were cultured with wild type peptide
NS3358-375, concanavalin A (ConA) (positive control)
and medium alone. The ratios of CD25
+ and CD25
+TGF-b
+ cells were ranged 13.9~17.8% and 5.04~6.16%,
respectively(see Additional File 3, Figure S2A-B). We
also observed CD25
+IL-10
+ Tr1 cells induced by HCV
peptide and its variants at a frequency of about 5~12%
(Figure 3B, the sum of the lower and upper right quad-
rant), compared to normal controls (1~3%, Figure S2B).
Over 90% of such Tr1 cells from the HCV infected
patient were also TGF-b
+ (Figure 3B), whereas less than
50% of CD25
+IL-10
+ cells from the normal control were
TGF-b
+ (Figure S2B). The percentages of IFN-g
+ cells
(including both CD25
+ and CD25
-) were less than 1%
for the patient and ranged 1~4% for the normal control
suggesting an attenuated Th1 response in HCV
infection.
The fact that deletion of CD25
+ cells only partially
reverted the suppressions by both VP1 and VP2 sug-
gested the possibility of the involvement of CD25
- sup-
pressors in the reaction. When CD4
+CD25
- cells were
analyzed, higher percentages of CD25
-TGF-b
+ cells were
observed for VP1 (20.8%) and VP2 (21.0%) than wild
type NS3358-375 (12.7%, Figure 3D), suggesting such
CD25
- Th3 cells could be the major source of TGF-b
+
cells that played an important role in the inhibition
induced by VP1. The percentage of CD25
- Th3 cells
from the normal control ranged 2.3~2.8% (see Addi-
tional File 3, Figure S2C). These data are consistent
with another report that showed the induction of CD4
+CD25
- Tregs by TGF-b in murine peripheral T cells
[42]. We observed higher CD25
- and CD25
+ IL-10-
secreting Tr1 cells induced by VP1 (CD25
-: 11.4%,
CD25
+: 5.9%) with cells obtained at about 1.5 years of
HCV infection compared to the Tr1 cells stimulated by
wild type peptide (7.6% and 2.9%) and VP2 (5.9% and
2.3%) (see Additional File 4, Figure S3). In addition,
using PBMCs from another DRB1*15
+ patient infected
with HCV over 20 years, more CD25
-IL-10
+ Tr1 cells
were induced by VP1 (33%) than those exposed to either
wild type peptide (25%) or VP2 (17%) (see Additional
File 5, Figure S4). This data s suggest that IL-10, CD25
-
TGF-b
+ Th3 and CD4
+IL-10
+ Tr1 cells were involved in
the immune inhibition by VP1, and CD25
+TGF-b
+ Th3
cells played a critical role in the inhibition by VP2.
For further confirmation, we determined the levels
and phenotypes of additional five HCV-infected patients
who are positive for HLA-DRB1*15 (P2-P6, see Addi-
tional File 1, Table S1). The results of those patients
plus patient B3019 are summarized in Table 2. Taken
together, our data strongly support the hypothesis that
antigenic variants of HCV are able to induce immune
suppression through up-regulatory Th3, Tr1 cells and
IL-10.
Characteristics of Tregs driven by antigenic variants
The transcription factor forkhead box P3 (Foxp3)h a s
been found to be a crucial regulator of immune func-
tion and is required for development of CD4
+CD25
+
Tregs [43]. TGF-b has recently been reported to have
an essential role in both inducing and maintaining
Foxp3 in peripheral CD25
+ and CD25
- Tregs[44]. In
addition, cytotoxic T lymphocyte-associated antigen 4
(CTLA-4, or CD152) is also expressed on CD4
+CD25
+
Tregs, and CTLA-4 signaling is required for their func-
tion[45]. Therefore, we asked whether the variant-dri-
ven CD25
- and CD25
+ Tregs observed in HCV
infection express CTLA-4 and Foxp3. The expression
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+CD25
+ and CD4
+CD25
- cells were determined by intracellular staining
and flow cytometry. As shown in Figure 4, the levels
of Foxp3 (Figure 4A) and CTLA-4 (Figure 4B) induced
by exposure to VP1 and VP2 are significantly higher in
CD25
+ cells compared to those induced by wild type
peptide NS3358-375 (Figure 4A:107, 121 versus 77.8 for
Foxp3; Figure 4B: 54.8, 61.5 versus 38.4 for CTLA-4).
The wild type peptide NS3358-375 actually down-
regulated the expression of Foxp3 and CTLA-4 com-
pared to cells cultured with medium alone. We did not
detect significant levels of CTLA-4 and Foxp3 expres-
sion in/on CD4
+CD25
- cells. This observation suggests
that: 1) the features of antigen-inducible CD4
+CD25
+
Tregs in HCV infection are similar to those of natural
CD4
+CD25
+ Tregs although their developmental path-
ways are distinct; 2) the antigen-inducible CD25
- Tregs
driven by antigenic variants are different from the
CD25+ CD25+ CD25+ CD25+ CD25+
CD25- CD25- CD25- CD25- CD25-
T
G
F
-
β
IL-10
IL-10
T
G
F
-
β
Isotype control Medium VP2 NS3 358-375 VP1
A
B
C
D
Figure 3 Treg phenotypes induced by peptide NS3358-375 and variant pools VP1 and VP2. Cell culture adn purification of CD4
+ cells and
controls were the same as described in Figure 2. Intracellular staining and four-color flow cytometry using fluorescent-labeled antibodies to
human CD25, IFN-g, TGF-b and IL-10 were performed with purified CD4
+ cells. A pool from each test was used as an isotype control. A:
Percentages of CD25
+ gated CD4
+ cells. Note that the percentage of CD25
+ cells stimulated by VP2 is significantly higher. B: Percentages of Th3
and Tr1 cells. Note that 58~67% of the CD25
+ cells were TGF-b
+ (sum of the upper two quadrants). A majority of the CD25
+IL-10
+ cells were
also TGF-b
+ (the upper right quadrant). C: Percentages of CD25
- gated CD4
+ cells. D: Percentages of Th3 and Tr1 cells. Note that the
percentages of CD25
-TGF-b
+ cells stimulated by VP1 and VP2 are significantly higher than stimulation with wild type NS3358-375 and medium
alone. Two representatives of eight experiments are shown.
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- Tregs reported by others [44] because those
CD25
- Tregs do not express Foxp3.
In vivo evidence of Tr1 and Th3 cells in HCV infection
Considering the common existence of virus quasi-spe-
cies and antigenic variants in chronic HCV infection
[24,46], the immune evasion by antigenic variants
described above is unlikely an occasional event. If that is
true, we should detect elevated Tr1 and/or Th3 cells in
other HCV infected patients. Direct T-subset counting
by flow cytometry is a routing lab test for HIV infection
and the results reflect the T cell numbers in vivo. Simi-
larly, direct determinationo fT r e gp h e n o t y p e su s i n g
fresh PBMCs without in vitro culture would reflect
Tregs induced by HCV quasi-species including antigenic
variants in vivo. This approach can overcome or com-
plement the shortage of in vitro study because it can
better reflect an actual immune response in vivo as
being used for HIV infection.
Using freshly isolated PBMCs from six other patients
infected with HCV for about 2-5 years (see Additional
File 1, Table S1. P7-P12) and six healthy subjects (as
controls), we observed the following significant differ-
ences in HCV infected patients compared to the con-
trols: 1) higher CD4
+CD25
+ cells (17~34% versus
9~10%, p = 0.02); 2) 5~10 fold higher CD25
+ Th3 cells,
and 15~20 fold higher CD25
- Th3 cells; 3) higher CD25
+Il-10
+ Tr1 cells and the Tr1 fraction in two patients as
high as 14.4% and 16.2%; 4) the majority of the Tr1
cells are also TGF-b
+. In addition, patients with early
HCV infection have higher serum levels of IL-10 and
TGF-b (see Additional File 6, Figure S5). These results
demonstrate that Th3 and Tr1 cells are up-regulated in
early chronic HCV infection which is characteristic of
the immune modulation induced by virus quasi-species
and antigenic variants. These data are consistent with
the results presented above and provide evidence to
support the hypothesis that antigenic variants of HCV
are able to modulate a Th1 response through regulatory
Th3, Tr1 cells and IL-10.
Discussion
We have previously reported that CD4 antigenic var-
iants driven by immune selection clustered within
immune-dominant epitopes of the HCV nonstructural
three (NS3) gene [47]. Consistent to our data, a study
showed HCV escapes CD8 T-cell immune response in
HLA-B27+ patients through accumulated mutations
within an CD8 immune-dominant epitope, viral protein
RdRp which is bound by HLA-B27 molecule [28]. In the
CTLA-4 (CD152)
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Figure 4 Characteristics of antigen-driven CD25
+ and CD25
- Tregs.C e l l u l a rc u l t u r ea n ds e p a r a t i o no fC D 4
+ T cells and controls were the
same as described in Figure 2. The purified CD4
+ cells were stained with fluorescent-labeled antibodies for human CD25, CTLA-4 and Foxp3
followed by a flow cytometry assay. The effect of peptide NS3358-375 and variant pools VP1 and VP2 on expression of Foxp3 (A) and CTLA-4 (B)
on CD4
+CD25
- (blue) and CD4
+CD25
+ (red) T cells is shown. Median values for each population are shown in the boxes. One representative of
two experiments is shown.
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Page 9 of 13present study we provide evidence that naturally occur-
ring CD4 mutants of HCV act as antigenic variants that
transfer a host protective peripheral Th1 immune
response into an inhibitory Th3 or Tr1 response
through mutiple mechanisms including: 1) induction of
failed T cell activation and simultaneous induction of
CD4
+CD25
- Th3 and CD4
+IL-10
+ Tr1 cells; 2) up-regu-
lation of CD4
+CD25
+Th3 cells; and 3) direct inhibition
of IL-10.
The T cell receptor (TCR) exhibits an exquisite speci-
ficity for its antigen as demonstrated by the significantly
different biological outcomes induced by ligands that
differ by only a single amino acid [48]. VP 1 consisted
of variant peptides with single or double amino acid
substitutions located at the center of the core region of
the Th1 peptide (see Table 1), and they can be either
within or close to the TCR binding sites. Structural or
conformational alteration of TCR binding sites of pep-
tides can induce incomplete T cell activation that favors
induction of anergy [49]. Indeed, our data show that
VP1 peptides dramatically decreased CD4 T cell prolif-
eration (see Figure 1A). Furthermore, CD4 cells cultured
with VP1 expressed fewer T cell activation, as deter-
mined by low level expression of the T cell activation
markers of CD134 and CD45RB
high (see Additional File
7, Figure S6), providing direct evidence of failed T cell
activation by VP1 peptides. CD134 is expressed only on
activated T cells, particularly activated CD4
+ Tc e l l s
[50]. Interestingly, VP1 not only caused failed T-cell
activation, but also at the same time up-regulated the
regulatory cytokines IL-10 and TGF-b and either CD25
-
Th3 or Tr1 Tregs.
The amino acid substitutions in VP2 peptides are not
likely involved in TCR binding directly since they are
located outside the core region of the Th1 peptide (see
Table 1). However, they may act as interface-disrupting
residues which can actively disrupt the TCR binding
ability [51]. It is also possible that the amino acid substi-
tutions in VP2 peptides induce conformational changes
either in the TCR or in the HLA molecules on APCs.
Minor changes at the TCR or APC level could have a
significant impact on T cell responses, since specific T
cell recognition is strictly determined [49]. In support of
this hypothesis, T cells pulsed with VP2 peptides failed
to respond to the subsequent challenge with the Th1
peptide NS3358-375 (see Figure 1). This induction of
anergy was not due to incomplete T cell activation since
VP2 stimulated even higher levels of the T cell activa-
tion marker CD134 than wild type peptide (see Addi-
tional File 7, Figure S6A). Because up-regulation of
CD134 expression by VP2 was accompanied by the
highest levels of TGF-b and CD25
+ Th3 Tregs, higher
CD134 expression by VP2 might reflect activation of
pathways related to CD25
+ Treg differentiation instead
of T effecter activation. These results suggest that VP2
peptides also work as antigenic variants through a dis-
tinct pathway.
Collectively, the immune evasion by antigenic variants
has two features. First, the modulatory effect of anti-
genic variants on CD4 response is effective and exten-
sive. As low as 0.1 μM of variant peptide and as many
as 17 out of 18 (94%) of the antigenic variants can
induce anergy (Figure 1 and unpublished data). Multiple
inhibitory components such as IL-10 as well as Th3 and
Tr1 cells were induced by these variants (see Figure 2,
3). Second, induction of a deviated immune response or
antigen-inducible Tregs is favored over induction of a
Th1 response. It seems that a specific Th1 response
requires strict TCR engagement and even single amino
acid alteration of a Th1 peptide can shift the direction
of a Th1 response to an inhibitory direction [48]. In
contrast, induction of anergy or antigen-inducible Tregs
does not require strict TCR engagement since extensive
variants induced similar results of anergy and up-regu-
lated Tregs although they may use different pathways
[49]. These features provide a potential mechanism by
which a minority of circulating antigenic variants can
effectively suppress a protective Th1 response to native
viral epitopes. Together with the feature of high mut-
ability of HCV, this hypothesis can explain why the
majority of HCV infected patients progress to persistent
infection.
Consistent with the studies by others [34], our current
data show an elevated ratio of IL-10
+ Tr1 cells in the
early course (less than 5 years) of HCV infection (see
Table 2). Moreover, the suppression of T cell prolifera-
tion by VP1 peptides was abrogated by anti-IL-10 anti-
body (see Figure 2B). We detected both CD25
- and
CD25
+ Tr1 cells induced by VP1 as early as 1.5 years of
HCV infection (see Additional File 3, Figure S2) whereas
the majority of IL-10
+ cells beyond 2.5 years of infection
were predominantly CD25
+.
Regardless the cytokine sources, VP1 consistently pro-
duced higher levels of IL-10 and CD25
- Th3 cells, which
directly contributed to the immune modulation by this
group of variants. These data suggest that as antigenic
variants such as VP1 evolved in the earlier course of
HCV infection they initiate the regulatory mechanisms
mediated by IL-10 and Th3 cells in order to escape
immune pressure. Such VP1 variants up-regulate immu-
noregulatory IL-10 and Th3 cells that suppressed a pro-
tective Th1 response but did not influence the Th3 or
Tr1 response. As a result of the existense of VP1, the
balance of immune responses shifts to a Tr1 or Th3
profile as we observed in our previous [39] and present
studies. This hypothesis is further supported by our data
that: 1) the majority of variants as early as about one
year into HCV infection consist of VP1 (see Table 1)
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years have significantly higher percentages of Tr1 and/
or Th3 cells and higher serum levels of IL-10 and TGF-
b (see Table 2 and Additional File 5, Figure S4).
TGF-b-secreting CD25
+ and CD25
- Th3 cells induced
by antigenic variants occurred in early years of HCV
infection. The immune inhibition induced by VP1 was
abolished completely by deletion of TGF-b
+ cells rather
than by blocking or deletion of CD25
+ cells, suggesting
that this suppressive pathway by VP1 was not CD25-
dependent but actually TGF-b-dependent. In contrast,
the suppression induced by VP2 was CD25 and TGF-b
dependent because either antibody to CD25 or deletion
of CD25
+ and TGF-b
+ cells eliminated the suppressive
effect. Accordingly, higher ratios of CD25
-TGF-b
+ Th3
cells were observed for VP1 and VP2 (see Figure 3D)
and VP2 dramatically increased the ratio of CD25
+TGF-
b
+ Th3 cells (see Figure 3B). In the presence of high
levels of IL-2 and TGF-b produced by exposure to VP2
(see Figure 2G), CD25
-TGF-b
+ cells likely differentiated
to become CD25
+TGF-b
+ cells [52]. The fact that dele-
tion of TGF-b
+ cells instead of neutralization of TGF-b
reversed the immune suppression by both VP1 and VP2
indicates that cell contact of TGF-b-bound cells instead
of soluble TGF-b is necessary for the inhibitory effects.
These data are consistent with the results reported by
Carrier et al. Their data showed that the suppressive
effect of TGF-b on T cell responses is due to the induc-
tion of Tregs instead of direct inhibition of TGF-b on T
cell proliferation[44]. The finding of higher ratio of
CD25
-TGF-b
+ cells induced by VP1 supports the
hypothesis that CD25
- Th3 cells are the major source of
TGF-b
+ cells that play an important role in the immune
evasion induced by VP1.
A recent study suggested that CD4 T cells function
through other mechanisms rather than exerting immune
selection in HCV infection [53]. Consistently, the cur-
rent study indicates possible inhibitory mechanisms
used by CD4 T cells in chronic HCV infection. The
immune modulation can be initiated or enhanced by
naturally occurring antigenic variants of a CD4 epitope.
This role of CD4 cells would in turn attenuate the func-
tional efficiency of CD8 T cells that favors HCV persis-
tence. It should be noted that data being obtained with
PBMCs collected at one time point of an infection
course would only represent “snapshots” of the immune
response during entire HCV infection. Additional stu-
dies would be needed to precisely correlate the occur-
rence of antigenic variants with the loss or shift of
HCV-specific T cell responses. The phenotypes of
immune responses may vary somewhat among different
subjects depending on the HCV time continuum and
the subjects. Samples collected at different time points
from any given subject might also induce variable
results. However, the overall trend of immune inhibition
i n d u c e db yC D 4v a r i a n t sd u r i n gt h ec o u r s eo fH C V
infection was consistent.
Conclusions
In summary, our data revealed multiple mechanisms of
peripheral immune modulation initiated or enhanced by
naturally occurring antigenic variants of a CD4 epitope
in the early course of HCV infection. Antigenic variants
o faT h 1p e p t i d ec a nd o w n - r e g u l a t eaT h 1r e s p o n s eb y
hampering T cell activation and simultaneous induction
of IL-10, CD25
-TGF-b
+ Th3 and CD4
+IL-10
+ Tr1 cells.
IL-10 alone can directly suppress T cell proliferation
and Th1 cytokine production. In addition, other HCV
variants tend to induce higher levels of TGF-b that pro-
mote differentiation of CD25
+ Th3 suppressors. The
modulation of antigenic variants on CD4 response is
efficient and extensive that is likely critical in viral
persistence.
Additional material
Additional file 1: Table S1. The information of HCV-infected patients.
The information of HCV-infected patients.
Additional file 2: Figure S1. An example of CD4+CD25+ cells achieved
by culturing HCV-infected PBMCs with variant peptide pool VP1 at
presence (B) or absence (A) of anti-TGF-bantibodies; and CD4+CD25+
cells achieved by culturing HCV-infected PBMCs with (D) or without (C)
TGF-b
+cell deletion. Either anti-TGF-b antibodies or deletion of TGF-b
+cells significantly reduced CD4+CD25+ cells. Two representatives of four
experiments are shown.
Additional file 3: Figure S2. CD4+CD25+ and CD4+CD25- Tregs of a
HCV- healthy individual. Experiments, controls, and data analysis were the
same as described in Figure 4. A: Percentages of CD25+ and CD25-
gated CD4+ cells. B: Percentages of CD25+ Th3 and Tr1 cells. C:
Percentages of CD25- Th3 and Tr1 cells. A single representative of three
experiments is shown.
Additional file 4: Figure S3. Treg phenotypes induced by peptide
NS3358-375 and variant pools VP1 and VP2 at about 1.5 years post HCV
infection. Cell culture and purification of CD4
+ cells and controls were
the same as described in Figure 4. Intracellular staining of purified CD4+
cells was performed using fluorescent-labeled antibodies to human
CD25, IFN-g, TGF-b and IL-10. A: Percentages of CD25
-IL-10
+ Tr1 cells. B:
Percentages of CD25
+IL-10
+ Tr1 cells. A single representative of three
experiments is shown.
Additional file 5: Figure S4. Treg phenotypes from a patient infected
with HCV for over 20 years. Cell culture, purification of CD4
+ cells,
controls, intracellular staining and flow cytometry analysis were the same
as described in Figure 2. Note that VP1 peptides induced higher CD25
-Il-
10
+ Tr1 cells than wild type peptide NS3358-375, VP2 peptides and
medium alone.
Additional file 6: Figure S5. Serum levels of IL-10 and TGF-b. C: HCV-
healthy controls; P: HCV+ patients.
Additional file 7: Figure S6. HCV variants induced incomplete T cell
activation and/or up-regulated CD45RB
low Tregs. PBMCs were cultured
with peptide NS3358-375 (5 μM) and variant pools (1 μM/each peptide) for
66 hours followed by positive selection of CD4
+ T cells with anti-human
CD4 antibodies and magnetic beads. The CD4
+ cells obtained were then
stained with fluorescent-labeled antibodies to human CD134 (OX40), and
CD45RB and analyzed using a three-color flow cytometer. PBMCs
cultured with medium alone were used as control. The effect of peptide
NS3358-375 and variant pools VP1 and VP2 on expression of CD134 (A)
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Page 11 of 13and CD45RB (B) on CD4 T cells is demonstrated. A representative of two
experiments is shown.
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